NRAS and renal cell carcinoma: All MM patients harbored a BRAF and NRAS wild-type tumor and received a median of 3 lines of prior therapies including ICIs, whereas the majority of patients with RCC received at least 3 lines of tyrosine kinase inhibitors (TKIs).